Research
Hormonal
Obesity in Type 1 Diabetes is associated with increased cardiometabolic risk, higher insulin requirements, and an enhanced risk of chronic complications compared to normal-weight T1D patients.
Obesity in T1D is not just about weight; it significantly increases the risk of heart disease, kidney issues, and eye problems due to insulin resistance. Managing weight is critical for long-term complication prevention.
GoodSupportsHIGH confidence
Patients with T1D and obesity are characterized by the presence of insulin resistance, of high insulin requirements, have a greater cardiometabolic risk and an enhanced risk of developing chronic complications when compared to normal-weight persons with T1D.
Why this rating
Supported by multiple observational studies and registries cited in the paper.
Source
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Núria Vilarrasa et al. · Diabetes Metabolic Syndrome and Obesity · 2021
DOI 10.2147/dmso.s223618
narrative_reviewCited 88×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- A comprehensive lifestyle intervention combining a hypocaloric Mediterranean diet, structured physical activity, and cognitive behavioral therapy is the recommended clinical practice for managing obesity in Type 1 Diabetes, despite evidence being scarce.Moderate
- Bariatric surgery is beneficial for obtaining substantial and long-term weight loss and reducing cardiovascular risk in patients with severe obesity and Type 1 Diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →